Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 98-102

  Karino, Fumi ^a   Deguchi, Naoko ^a   Kanda, Hibiki ^a   Ohe, Miki ^a   Kondo, Keiichi ^a   Tada, Mitsuhiro ^a   Kuraki, Takashige ^a   Nishimura, Nobuhiro ^b   Moriyama, Hidehiko ^b   Ikawa, Kazuro ^c   Morikawa, Norifumi ^c   Isobe, Takeshi ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Biapenem; Pharmacokinetics Pharmacodynamics; Pneumonia in the elderly

Indexed keywords

BIAPENEM; C REACTIVE PROTEIN; CLARITHROMYCIN; CLINDAMYCIN; CREATININE; MINOCYCLINE; PREDNISONE;

AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY TEMPERATURE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISSEMINATED INTRAVASCULAR CLOTTING; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GENERAL CONDITION DETERIORATION; GLOMERULUS FILTRATION RATE; HUMAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MALE; NAUSEA; PNEUMONIA; PROSPECTIVE STUDY; SIDE EFFECT; THORAX RADIOGRAPHY;

EID: 84874109286     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0463-y     Document Type: Article

References (9)

1. Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419-28.
2. Niki Y, The JRS. Guideline for the management of hospital-acquired pneumonia in adults. Nihon Naika Gakkai Zasshi. 2008;97:2578-83.
3. Hikida M, Kawashima K, Yoshida M, Mitsuhashi S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother. 1992;30:129-34.
4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
5. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999; 110-23.
6. Aoki A, Inoue Y, Sato T, Kuwabara H, Nishihira R, Uchida D, et al. Clinical evaluation on biapenem for respiratory infections in elderly patients: safety for renal function. Antibiot Chemother. 2003;19:1359-64.
7. Hamada H, Abe M, Yamamoto A, Katayama H, Hirayama T, Aibara Y, et al. Evaluation of clinical usefulness of biapenem in the treatment of elderly patients with bacterial pneumonia. J New Rem Clin. 2009;58:1961-8.
8. Ikawa K, Morikawa N, Hayato S, Nishikawa Y, Ikeda K. Development of software support tool for planning administration of biapenem, a carbapenem antibacterial agent, based on pharmacokinetic/pharmacodynamic approach and Monte Carlo simulation. Jpn J Pharm Health Care Sci. 2006;32:622-8.
9. Morikawa N, Nishikawa Y, Ikeda K, Ikawa K, Miki M, Miyagawa S, et al. Development of real-time therapeutic drug monitoring system for biapenem based on pharmacokinetic/pharmacodynamic theory about antimicrobial agents. Jpn J TDM. 2006;23:229-32.